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OBJECTIVES: Health care workers are a population at risk of Latent Tuberculosis 
Infection (LTI), which is usually detected by the Tuberculin Skin Test (TST). In vitro 
immunological tests such as QuantiFERON-TB Gold® (QFT-G) have been recently 
recommended for LTI screening in health care workers. We compared direct and 
indirect costs of two LTI screening strategies among health care workers in Spain: 
TST and QFT-G. METHODS: This was a comparative cost study conducted from a 
societal perspective, using data on costs and results from a prospective observational 
study carried out in a Spanish public hospital, where the 2 screening alternatives were 
concurrently applied to a cohort of 134 health care workers. RESULTS: In a base-case 
analysis, the costs of the QFT-G test amounted c42.5 per screened health care worker 
and those of the TST c39.5. Both tests varied in their cost structure: in the case of 
TST, most of the total costs (70%) were indirect costs, basically time spent by the 
participants, whereas QFT-G was more expensive in terms of fungible material, which 
meant 50% of the total costs. The results are sensitive to the hourly wages of the 
participants and to the estimation of the time spent by them in the tests. CONCLU-
SIONS: This cost study showed that, in the conditions of Spanish health care system, 
the societal costs of the new QFT-G are comparable to those of the TST; however, 
their cost structures vary considerably. Therefore, these results could change if applied 
in other countries with different relation between salaries and prices.
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OBJECTIVES: To determine if the average cost of medical care among cystic ﬁ brosis 
(CF) patients with Pseudomonas aeruginosa (PA) infection is different across age-
groups. METHODS: Data were derived from MarketScan claims database, which 
captures person-speciﬁ c direct medical utilization, expenditures, and enrollment from 
approximately 150 payers. a retrospective cross-sectional study design was used. CF 
subjects with an initial claim for a PA infection were identiﬁ ed using international 
classiﬁ cation of diseases diagnosis codes of 277.0 and 482.1, respectively. Demo-
graphic information from administrative claims and health care utilization and costs 
from medical and pharmacy claims were extracted for 12 months pre and post initial 
PA claim. All resource use and costs were annualized and compared across 7 age-
groups with parametric (ANOVA) and Duncan’s post-hoc tests using SAS version 9.2. 
RESULTS: A total of 347 CF subjects with PA infection met the study criteria with 
mean age 19.9 (SD: 15.4) years and 47.8% females. a monotonic trend of increasing 
(P < 0.05) overall post period costs was observed across the 7 age-groups. Example, 
children 0–4 years had the lowest (P < 0.05) overall post costs of $31,569 (median = 
$22,887) vs. $95,024 (median = $36,783) for adults 45–64 years. a similar trend with 
the exception of age group 30–44, was observed with PA-related costs as well. Mean 
and median per patient per year PA-related costs were lowest in children 0–4 years 
($12,472, $3,572) compared to the oldest age-group of 45–64 years ($26,673, 
$3,311). In general, total prescription claims and outpatient visits, and PA-related 
inpatient visits increased with increasing age groups. Among children, PA-related 
prescription claims were statistically higher. For example, mean PA-related prescrip-
tion claims were 1.4 vs. 3.8 in the 0–4 vs. 15–19 groups (P < 0.05). CONCLUSIONS: 
Overall and PA-related health care resource use and costs tended to vary across age 
groups. Future research needs to explore the underlying reasons for this trend.
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OBJECTIVES: There is a paucity of data on the long-term (i.e., post-hospital dis-
charge) economic and clinical burden of invasive meningococcal disease (IMD) and 
its related complications among IMD survivors. The objective of this study was to 
compare health care utilization and costs between IMD survivors with and without 
related complications. METHODS: We conducted a retrospective cohort analysis of 
the Ingenix Impact database (1997–2009). Patients with an inpatient admission for 
IMD (ICD-9-CM: 036.x) and continuous health plan enrollment for ≥6 months before 
and ≥12 months after the initial IMD hospitalization were selected. Patients were 
further classiﬁ ed based on the presence (complicated IMD) or absence (uncomplicated 
IMD) of a diagnosis code for relevant clinical sequelae (identiﬁ ed based on literature 
review and clinical expertise) during the 12-month follow-up period. Health care 
utilization and costs (in 2009 US$) incurred during the 12-month follow-up period 
were compared between patients in the complicated and uncomplicated IMD groups 
using univariate and multivariable regression analyses. RESULTS: Among 343 IMD 
patients identiﬁ ed, stroke (14.3%), seizure (11.7%) and hearing loss (10.5%) were 
the most commonly observed complications, with 34.1% experiencing ≥1 complica-
tion. Signiﬁ cant differences in health care utilization and costs were observed, with 
the largest between-group difference in follow-up costs being for inpatient services 
(mean [95% CI]: $72,512 [$6,439] for complicated cases vs. $24,679 [$1,234] for 
uncomplicated IMD; P < 0.001). Large differences were also observed for rehabilita-
tive services ($24,405 [$21,418] vs. $159 [$116]; P < 0.05) and total health care costs 
($97,854 [$9,248] vs. $32,239 [$1,611]; P < 0.001). Risk of re-hospitalization fol-
lowing discharge from the initial IMD admission was higher among complicated IMD 
patients (hazard ratio = 1.69 [95% CI] = 1.04–2.74) vs. uncomplicated cases. CON-
CLUSIONS: Driven mainly be the need for repeat hospitalization, the presence of 
serious complications in cases of IMD increased health care utilization and costs by 
almost 3 fold compared to uncomplicated cases during 12 months post-diagnosis.
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OBJECTIVES: This study sought to estimate the direct medical costs associated treat-
ing candidemia in Korea. METHODS: This incidence based, cost-of-illness study 
collected retrospective data of 200 patients in 4 tertiary hospitals. The cost data tar-
geted for adult patients (≥19 years) diagnosed as candidemia through blood culture. 
We assessed the costs attributable to candidemia by examining resources utilization 
during candidemia treatment period. The medical costs were calculated by multiplying 
quantity of resource utilization by unit cost of according resource. RESULTS: The 
enrolled patients were 54.0% male, average 65.3 yrs old. The average length of stay 
attributable to candidemia was 16.3 days. After 6 weeks follow up, only 2 patients 
were relapsed, otherwise all-cause mortality rate was 66.0%. The estimated average 
direct medical costs of candidemia were KRW 4,723,160. The resources consisted of 
hospitalization (KRW 1,308,521, 27.7%), medication (KRW 1,310,739, 27.8%), lab 
test (KRW 489,818, 10.4%), imaging test (KRW 157,633, 3.3%), procedure/surgery 
(KRW 113,774, 2.4%) and other medical treatment (KRW 1,342,675, 28.4%). The 
main occupied costs were those of hospitalization, medication and when other medical 
treatment resources (e.g, hemodialysis, blood transfusion) were utilized, the costs 
tended to sensitively increase. According to admission type, costs for ICU (SICU: n = 
24, KRW 8,837,825, MICU: n = 51, KRW 6,914,280) were higher than those for 
general ward (n = 125), KRW 3,039,167. Analysis by baseline disease/condition 
revealed that the costs for transplant (n = 8, KRW 10,070,472), HIV/AIDS (n = 2, 
KRW 25,426,018) were higher than others (cancer: n = 103, KRW 3,658,142, central 
catheterization: n = 101, KRW 5,554,520, surgery: n = 68, KRW 5,050,941). The 
costs for C.albicans (n = 90) were KRW 3,878,166 and for non C.albicans (n = 110) 
were KRW 5,414,518. CONCLUSIONS: This study is signiﬁ cant in that it estimated 
cost-of-illness of candidemia by examining the health resources consumption and 
assessing the costs attributable to candidemia.
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OBJECTIVES: Signiﬁ cant attention is being focused on reducing surgical site infec-
tions (SSI) in the US and numerous national initiatives have been put into place to 
achieve measurable reductions. The purpose of the study was to examine the economic 
impact of therapeutic antibiotic (TA) utilization as an indicator of postoperative SSI 
between two time periods. METHODS: Premier inpatient database was utilized for 
assessing length of stay (LOS) and costs. Two time periods identiﬁ ed, 2005–2008 
(period 1) and 2009 (period 2) with 1,138,989 patients discharged in 2005–2008 and 
305,073 discharged in 2009. The patients with non-SSI nosocomial infections were 
excluded. TA usage was determined by the antibiotic administration after day 4 of 
surgery (TA utilization rate: 0.61% in 2005–2008; 0.75% in 2009). Multivariate 
analysis used to assess the effects of using TA on LOS and total costs outcomes. 
RESULTS: Patients receiving TA had signiﬁ cantly higher LOS and costs for both time 
periods (P < 0.001). Average LOS for patients receiving TA was 12.2 and 12.6 for 
periods 1 and 2 respectively. Mean post-surgical LOS was 9.8 and 10.0. Patients not 
receiving TA had average LOS of 4.6 and 4.6 in periods 1 and 2 and mean post-
surgical LOS was 3.9 and 3.8 for periods 1 and 2. Mean (SD) total costs for TA 
patients were signiﬁ cantly higher, $28,601 ($31,892) in period 1 and $32,751 
($38,194) in period 2, compared to $15,336 ($33,406) and $15,412 ($20,311) for 
patients not receiving TA. Predictors for signiﬁ cantly higher risk of TA use included 
General Surgery, Non-cardiac Thoracic procedures, bed-size under 500 or Rural, and 
Staples or Non-absorbable sutures usage. CONCLUSIONS: These ﬁ ndings suggest 
minimal impact on the SSI economic burden indicated by similar trends in antimicro-
bial utilization, costs and LOS over time. Further studies are warranted assessing the 
role of innovative technology to improve patient outcomes while reducing antibiotic 
utilization and LOS.
